Sam Rasty, PlateletBio CEO (Oxford Biomedica, via Website)

Platelet­Bio an­nounces $75.5M Se­ries B to ex­tend au­toim­mune cell ther­a­py

More than two years af­ter Platelet­Bio land­ed its first round of fundrais­ing and a con­tract with the US gov­ern­ment, the com­pa­ny an­nounced its Se­ries B round Thurs­day.

The pre­clin­i­cal stage biotech out of Wa­ter­town, MA an­nounced it raised $75.5 mil­lion. The round was led by new in­vestors Sym­Bio­sis, K2 HealthVen­tures, and Ox­ford Fi­nance, and al­ready-ex­ist­ing in­vestors.

The fi­nanc­ing will go to­ward pre­clin­i­cal de­vel­op­ment of its lead platelet-like cell pro­gram as a ther­a­py for the au­toim­mune dis­ease im­mune throbo­cy­tope­nia. It will help fur­ther de­vel­op its plat­form and man­u­fac­tur­ing ca­pa­bil­i­ties, and as a re­sult, the man­ag­ing part­ner of Sym­Bio­sis, Chi­dozie Ug­wum­ba, will join the board of di­rec­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.